Galectin-3: A Cancer Marker with Therapeutic Applications

作者: Anita Gupta

DOI: 10.1007/978-3-7091-1065-2_13

关键词:

摘要: Galectin-3 (Gal-3) is a pleiotropic carbohydrate-binding protein involved in variety of normal and pathological biological processes. Its properties constitute the basis for cell-cell cell-matrix interactions ( Chap. 12) cancer progression. Gal-3 known to be expressed various neoplasms including thyroid tumors. widely spread among different types cells tissues, found intracellularly nucleus cytoplasm or secreted via non-classical pathway outside cell, thus being on cell surface extracellular space. RNA processing cycle regulation through activation transcription factors when translocated nucleus. affects numerous processes seems physiological pathophysiological conditions. Most members galectin family galectin-1 possess apoptotic activities, whereas possesses anti-apoptotic activity (Dumic et al. 2006). Studies lead recognition as diagnostic/prognostic marker specific types, such prostate (Califice 2004b). Though immune system recognizes diverse antigens, tumors can evade response, therefore growing progressing. However, there strong evidence indicating that galectins function human tumor microenvironment complex process influenced by circumstances.

参考文章(176)
Mariana Rodríguez Zubieta, David Furman, Marcela Barrio, Alicia Inés Bravo, Enzo Domenichini, José Mordoh, Galectin-3 Expression Correlates with Apoptosis of Tumor-Associated Lymphocytes in Human Melanoma Biopsies The American Journal of Pathology. ,vol. 168, pp. 1666- 1675 ,(2006) , 10.2353/AJPATH.2006.050971
Alessandra Gasbarri, Clorinda Marchetti, Giorgio Iervasi, Antonio Bottoni, Andrea Nicolini, Armando Bartolazzi, Angelo Carpi, From the bench to the bedside. Galectin-3 immunodetection for improving the preoperative diagnosis of the follicular thyroid nodules. Biomedicine & Pharmacotherapy. ,vol. 58, pp. 356- 359 ,(2004) , 10.1016/J.BIOPHA.2004.05.004
V. A Heinzelmann-Schwarz, R. A Scolyer, J. P Scurry, A. N Smith, M. Gardiner-Garden, A. V Biankin, S. Baron-Hay, C. Scott, R. L Ward, D. Fink, N. F Hacker, R. L Sutherland, P. M O'Brien, Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries. Journal of Clinical Pathology. ,vol. 60, pp. 622- 626 ,(2007) , 10.1136/JCP.2005.034223
Bogdan Galusca, Jean Marc Dumollard, Sandrine Lassandre, Alain Niveleau, Jean Michel Prades, Bruno Estour, Michel Peoc’h, Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia Virchows Archiv. ,vol. 447, pp. 18- 23 ,(2005) , 10.1007/S00428-005-1268-5
Stéphane Califice, Vincent Castronovo, Marc Bracke, Frédéric van den Brûle, Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3 Oncogene. ,vol. 23, pp. 7527- 7536 ,(2004) , 10.1038/SJ.ONC.1207997
S Langbein, Joachim Brade, Jasmin Katrin Badawi, M Hatzinger, H Kaltner, M Lensch, K Specht, S André, Ulrich Brinck, P Alken, H‐J Gabius, None, Gene-expression signature of adhesion/growth-regulatory tissue lectins (galectins) in transitional cell cancer and its prognostic relevance Histopathology. ,vol. 51, pp. 681- 690 ,(2007) , 10.1111/J.1365-2559.2007.02852.X
Pascal O. Berberat, Helmut Friess, Li Wang, Zhaowen Zhu, Thorsten Bley, Luciano Frigeri, Arthur Zimmermann, Markus W. Büchler, Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. Journal of Histochemistry and Cytochemistry. ,vol. 49, pp. 539- 549 ,(2001) , 10.1177/002215540104900414
Josiah Ochieng, Maria L. Leite-Browning, Paula Warfield, Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochemical and Biophysical Research Communications. ,vol. 246, pp. 788- 791 ,(1998) , 10.1006/BBRC.1998.8708
T. Yoshii, H. Inohara, Y. Takenaka, Y. Honjo, S. Akahani, T. Nomura, A. Raz, T. Kubo, Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. International Journal of Oncology. ,vol. 18, pp. 787- 792 ,(2001) , 10.3892/IJO.18.4.787